Supplemental material
Journal of Medical Economics
Volume 25, 2022 - Issue 1
Intracranial Hemorrhage
Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor-related intracranial hemorrhage in the US
John Fanikosa Brigham and Women’s Hospital, Boston, MA, USACorrespondence[email protected]
https://orcid.org/0000-0002-4218-2637
https://orcid.org/0000-0002-4218-2637, Joshua N. Goldsteinb Massachusetts General Hospital, Boston, MA, USAhttps://orcid.org/0000-0002-6406-1828
https://orcid.org/0000-0002-6406-1828, Belinda Lovelacec Alexion, AstraZeneca Rare Disease, Boston, MA, USAhttps://orcid.org/0000-0002-9986-2326
https://orcid.org/0000-0002-9986-2326, Anne C. Beaubrunc Alexion, AstraZeneca Rare Disease, Boston, MA, USAhttps://orcid.org/0000-0002-6009-119X
https://orcid.org/0000-0002-6009-119X, Robert S. Blissettd Maple Health Group, LLC, New York, NY, USAhttps://orcid.org/0000-0002-0540-8473
https://orcid.org/0000-0002-0540-8473 & Filipa Aragãod Maple Health Group, LLC, New York, NY, USA;e NOVA National School of Public Health, Public Health Research Centre, Universidade NOVA de Lisboa, Lisbon, Portugalhttps://orcid.org/0000-0003-3446-6725
https://orcid.org/0000-0003-3446-6725Related Research Data
Cost-effectiveness of andexanet alfa versus four-factor prothrombin complex concentrate for the treatment of oral factor Xa inhibitor���related intracranial hemorrhage in the US
Source:
Taylor & Francis
Linking provided by
